Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy

Elliott, Esther K; Haupt, Larisa M.; Griffiths, Lyn R.

doi:10.1007/s11248-020-00232-9

Cited by 5 publications

(3 citation statements)

References 59 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent computational efforts to identify new CRISPR systems uncovered a novel type of RNA targeting enzyme, Cas13. The diverse Cas13 family contains at least four known subtypes, including Cas13a, Cas13b, Cas13c, and Cas13d (Elliott et al, 2021). One of the most straightforward applications of Cas13 in vivo is targeted RNA knockdown using mammalian codon optimized Cas13 and guide expression vectors.…”

Section: Cas13 Systemmentioning

confidence: 99%

Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications

et al. 2022

View full text Add to dashboard Cite

Hematological malignancies (HM) are a group of neoplastic diseases that are usually heterogenous in nature due to the complex underlying genetic aberrations in which collaborating mutations enable cells to evade checkpoints that normally safeguard it against DNA damage and other disruptions of healthy cell growth. Research regarding chromosomal structural rearrangements and alterations, gene mutations, and functionality are currently being carried out to understand the genomics of these abnormalities. It is also becoming more evident that cross talk between the functional changes in transcription and proteins gives the characteristics of the disease although specific mutations may induce unique phenotypes. Functional genomics is vital in this aspect as it measures the complete genetic change in cancerous cells and seeks to integrate the dynamic changes in these networks to elucidate various cancer phenotypes. The advent of CRISPR technology has indeed provided a superfluity of benefits to mankind, as this versatile technology enables DNA editing in the genome. The CRISPR-Cas9 system is a precise genome editing tool, and it has revolutionized methodologies in the field of hematology. Currently, there are various CRISPR systems that are used to perform robust site-specific gene editing to study HM. Furthermore, experimental approaches that are based on CRISPR technology have created promising tools for developing effective hematological therapeutics. Therefore, this review will focus on diverse applications of CRISPR-based gene-editing tools in HM and its potential future trajectory. Collectively, this review will demonstrate the key roles of different CRISPR systems that are being used in HM, and the literature will be a representation of a critical step toward further understanding the biology of HM and the development of potential therapeutic approaches.

show abstract

Section: Cas13 Systemmentioning

confidence: 99%

Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…According to the diversity of cas genes and the mechanism of action for Cas proteins, CRISPR-Cas systems are categorized into 2 classes and further classified into six different types: type I to type VI [7,8]. Basic CRISPR research only constitutes a relatively small portion, and the majority of work rather focuses on the application of CRISPR-Cas systems in genome-editing, transcriptional control, biotechnology, and agriculture engineering [9][10][11][12][13][14][15]. Furthermore, how CRISPR-Cas systems interact with other genes in the prokaryote, such as endogenous gene targeting and virulence gene regulation, remains largely un-elucidated [16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses

Cui

Liu

et al. 2022

Mol Biomed

View full text Add to dashboard Cite

CRISPR-Cas systems are an immune defense mechanism that is widespread in archaea and bacteria against invasive phages or foreign genetic elements. In the last decade, CRISPR-Cas systems have been a leading gene-editing tool for agriculture (plant engineering), biotechnology, and human health (e.g., diagnosis and treatment of cancers and genetic diseases), benefitted from unprecedented discoveries of basic bacterial research. However, the functional complexity of CRISPR systems is far beyond the original scope of immune defense. CRISPR-Cas systems are implicated in influencing the expression of physiology and virulence genes and subsequently altering the formation of bacterial biofilm, drug resistance, invasive potency as well as bacterial own physiological characteristics. Moreover, increasing evidence supports that bacterial CRISPR-Cas systems might intriguingly influence mammalian immune responses through targeting endogenous genes, especially those relating to virulence; however, unfortunately, their underlying mechanisms are largely unclear. Nevertheless, the interaction between bacterial CRISPR-Cas systems and eukaryotic cells is complex with numerous mysteries that necessitate further investigation efforts. Here, we summarize the non-canonical functions of CRISPR-Cas that potentially impact bacterial physiology, pathogenicity, antimicrobial resistance, and thereby altering the courses of mammalian immune responses.

show abstract

“…Clustered regularly interspaced short palindromic repeats/ CRISPR associated nuclease (CRISPR/Cas) systems open new horizons for biosensors, for instance, CRISPR/Cas9, 15,16 CRISPR/ Cas12a, 17,18 CRISPR/Cas13a, [19][20][21] and CRISPR/Cas14a. [22][23][24] Among them, CRISPR/Cas12a and CRISPR/Cas13a are highly promising candidates for detecting DNA and RNA due to their trans-cleavage activity, which is the basis of signal amplification.…”

mentioning

confidence: 99%

Simultaneous detection of CaMV35S and T-nos utilizing CRISPR/Cas12a and Cas13a with multiplex-PCR (MPT-Cas12a/13a)

Cao¹,

Dong²,

Chen³

et al. 2022

Chem. Commun.

View full text Add to dashboard Cite

show abstract

Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy

Cited by 5 publications

References 59 publications

Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications

Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications

CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses

Simultaneous detection of CaMV35S and T-nos utilizing CRISPR/Cas12a and Cas13a with multiplex-PCR (MPT-Cas12a/13a)

Contact Info

Product

Resources

About